Moderna tunes vaccine platform to next potential viral threat: monkeypox

As cases of monkeypox continue to creep up worldwide, Moderna is turning its vaccine platform towards finding a jab to defend against the disease.

The Cambridge, Massachusetts biopharma, responsible for one of the most effective COVID-19 vaccines on the market, announced plans to explore potential vaccines for monkeypox at a “preclinical level," according to a Monday announcement.